Acute myeloid leukemia (AML), a fast-growing cancer with a 29% survival rate, is being redefined by a breakthrough in epigenomic mapping. A study published in Nature by researchers at Kyoto University and the Karolinska Institute identified 16 distinct epigenomic subgroups of AML based on chromatin accessibility. This research demonstrates that chromatin architecture, rather than gene mutations alone, provides a more accurate framework for predicting patient prognosis and treatment response.
Beyond Genetic Mutations: The Epigenomic Map
For decades, clinicians have relied on gene mutations to classify AML and guide treatment. However, these mutations often fail to explain why the disease manifests so differently across patients. According to the research team led by Seishi Ogawa, MD, PhD, and Yotaro Ochi, MD, PhD, of Kyoto University, and Sören Lehmann, MD, PhD, of the Karolinska Institute, the missing link is the epigenome—specifically, the accessibility of chromatin.
The study utilized a massive dataset of 1,563 patient samples, employing techniques such as ATAC-seq, RNA-seq, and DNA methylation to create the largest chromatin‑profiling effort ever conducted for any cancer. The data revealed 16 distinct epigenomic subgroups. Each subgroup possesses a unique “regulatory wiring,” defined by specific transcription-factor networks and super-enhancer architectures that remain stable across the patient’s leukemic population, as confirmed by single-cell ATAC-seq on over 280,000 cells.
The researchers found that even exhaustive decision-tree analyses of known driver mutations could not explain the identities of most AML subgroups. This suggests that the current classification systems used by the WHO and ICC may overlook significant biological drivers of the disease.
Clinical Implications for Targeted Therapy
The discovery of these 16 subgroups offers a practical path toward precision medicine. In both Swedish and Japanese patient cohorts, the chromatin-based profiles provided more accurate prognostic assessments than traditional genetic testing. More importantly, the findings uncovered unexpected drug sensitivities that could transform clinical trial design.
For example, researchers identified subgroups that responded to MEK inhibitors even in the absence of traditional RAS-pathway mutations. Another subgroup, characterized by RUNX1 mutations and a chromatin profile resembling early B-cell precursors, showed high sensitivity to ABL inhibitors. These insights indicate that chromatin architecture could serve as a foundational biomarker for selecting targeted therapies, regardless of whether a patient harbors a “classic” mutation.
Future Directions: The eCHROMA AML Atlas
To move these findings from the lab to the clinic, the research team has developed a 30-gene expression signature. This tool allows medical centers to identify high-risk chromatin subgroups using standard sequencing workflows, rather than requiring complex, specialized testing. Looking ahead, the group is focused on developing lower-cost diagnostic approaches to make this level of precision oncology accessible globally.
The newly generated eCHROMA AML atlas is intended to serve as a long-term resource for the broader cancer research community. By mapping how chromatin states influence cancer progression and drug response, the atlas provides a roadmap for discovering new therapeutic targets and refining treatment strategies for one of the most aggressive blood cancers.
When reviewing patient data for AML, look beyond the primary driver mutation. Emerging research suggests that the regulatory landscape—the “wiring” of the cancer cell—may be a more reliable predictor of how a patient will respond to specific kinase inhibitors.
Frequently Asked Questions
Why are current AML classification systems considered incomplete?
Current systems rely primarily on gene mutations. Research published in Nature suggests these mutations do not fully explain the heterogeneity of AML, as they fail to account for the role of the epigenome and chromatin accessibility in driving the cancer’s behavior.
What is the eCHROMA AML atlas?
The eCHROMA AML atlas is a comprehensive resource that maps the chromatin accessibility landscape of 1,563 AML patient samples. It is designed to help researchers identify new therapeutic targets and better understand the regulatory wiring of different leukemia subgroups.
How can clinicians use this information today?
The research team has distilled a 30-gene expression signature that can identify high-risk chromatin subgroups using standard, widely available sequencing workflows, allowing for better prognostic assessment and targeted therapy selection.
Are you interested in how precision oncology is changing blood cancer treatment? Subscribe to our newsletter for the latest updates on genomic and epigenomic research, or explore our archives for more deep dives into cancer biology.
